Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study

BACKGROUND: Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin (IL)‐17A and IL‐17F, which is currently under investigation for treatment of moderate‐to‐severe plaque psoriasis. Maintenance dosing every 4 weeks is well established with IL‐17 inhibitors for psoriasis. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliver, R., Krueger, J.G., Glatt, S., Vajjah, P., Mistry, C., Page, M., Edwards, H., Garcet, S., Li, X., Dizier, B., Maroof, A., Watling, M., el Baghdady, A., Baeten, D., Ionescu, L., Shaw, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303624/
https://www.ncbi.nlm.nih.gov/pubmed/34687214
http://dx.doi.org/10.1111/bjd.20827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303624/
https://www.ncbi.nlm.nih.gov/pubmed/34687214
http://dx.doi.org/10.1111/bjd.20827

Ejemplares similares